Understanding the RSV Threat

Respiratory Syncytial Virus ​(RSV) is a ubiquitous respiratory virus that typically causes mild, cold-like symptoms. However, for⁤ infants, young children, and older adults, RSV can lead to⁤ serious complications like bronchiolitis and pneumonia. Before the advent of these vaccines, RSV was responsible ⁢for‍ an estimated 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually among adults‍ 65 years and older‍ in the United States. Infants were⁤ similarly vulnerable, with ⁣a significant proportion requiring ⁤hospitalization.

The virus spreads through respiratory droplets produced when an infected person coughs or sneezes. Symptoms usually appear within 4 to 6 days of infection‌ and include a runny nose, ⁣decreased appetite, cough, sneezing, fever, and wheezing. While most people⁤ recover ⁤within​ a week or two, severe cases can require hospitalization and supportive care.

The New Vaccines: A Detailed Look

In May 2023, the Food and Drug Administration (FDA) approved two groundbreaking RSV vaccines: Arexvy (GSK) for older adults and Abrysvo (Pfizer) for ⁢both older adults and pregnant people ⁤to protect their babies. The data published in ‌the New England Journal of Medicine on October 23, 2025, provides a complete analysis of the clinical trial results and real-world impact of these vaccines.

Arexvy (GSK) – For Older Adults

Arexvy is a recombinant subunit vaccine ​containing a stabilized prefusion F protein. Clinical trials demonstrated approximately ​82.6% efficacy in preventing RSV-associated LRTD in adults 60‌ years and older. ⁢The trials, involving over 25,000 participants, showed a statistically significant reduction in severe illness requiring hospitalization. Common side effects included injection-site pain,fatigue,muscle aches,and headache.

abrysvo (Pfizer) ​- Dual Protection

Abrysvo also utilizes a prefusion F protein, but offers a unique‌ dual benefit. It’s approved for adults 60 ‌years and older *and* for pregnant people during the third trimester of pregnancy. When administered to pregnant individuals, Abrysvo stimulates the production of antibodies that are passed to the baby, providing protection during the first six months of life – a critical period when infants are most vulnerable to severe RSV disease. Clinical trials showed approximately 70% efficacy in​ preventing RSV-associated LRTD in infants born to vaccinated mothers. ⁣For older adults,Abrysvo demonstrated approximately 66.3% efficacy against RSV-associated LRTD.

Clinical Trial Data: A Closer Examination

The trials detailed in the New england Journal of Medicine (October ‌23, 2025) employed rigorous methodologies. ‍Participants were randomly assigned to receive either the vaccine or a placebo. Researchers then monitored the incidence of RSV-associated LRTD, ⁢defined as lower respiratory tract illness with at least one sign or symptom⁣ (cough, wheezing, shortness of breath, or increased respiratory ⁣rate) and requiring medical intervention.